Abstract: Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions.

Abstract: Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8+ T cells as DLI following allogeneic HCT, where the cells are administered at a suitable time following transplantation. The methods provide for a more complete donor chimerism, and have the further benefit of killing tumor cells without GVHD. The memory CD8+ T cells may include one or both of central and effector memory T cells, usually both.

Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.

Abstract: A pharmaceutical composition comprising at least 20 wt % of milk fat globules (MGFs) and at least one C12-C20 fatty acid, and being free of zinc oxide for treating skin disorders and/or cell abnormal proliferation disorders.

Abstract: The present invention provides methods and compositions for improving the efficacy of gene delivery such as viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies. The present invention also provides methods and compositions for improving cell therapy and gene therapy.

Abstract: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.

Abstract: The present disclosure relates generally to methods for the increased processing of tissue for the generation of cardiac stem cells, wherein the stem cells are suitable for use in cardiac stem cell therapy. In particular, several embodiments relate to the processing of allogeneic donor cardiac tissue for the generation of multiple patient doses of cardiac stem cells.

Abstract: This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.

Abstract: Methods for treating or preventing preeclampsia or eclampsia by administering adherent stromal cells are described. The adherent stromal cells may be derived from bone marrow, placenta, or adipose tissue. Also described is the use of adherent stromal cells for the manufacture of a medicament, and an article of manufacture comprising a packaging material which comprises a label for use in treating or preventing preeclampsia or eclampsia.

Abstract: The invention unexpectedly found that an isolated and modified QPSC population has multi-potentiality, including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). The QPSC population of the invention features a desirable immunomodulation ability, including inducing, enhancing, or suppressing an immune response and thus has potential value in the prevention and/or treatment of various immune diseases/disorders/conditions. The invention has effective homing ability and regulation ability in complement-dependent cytotoxicity, including the ability to block the activation of host complements and direct migration to the target area and the ability to enhance cell viability, and thus offers better cell protection and therapeutic efficacy in vivo in the prevention and/or treatment of various acute tissue injury, ischemic or degenerative diseases/disorders/conditions.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a by perproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: The present disclosure generally pertains to methods of treating non-healing wounds. Specifically, the method includes injecting amnion fluid derived cells along the periphery of the wound. The wound is then treated with a placental membrane material including a plurality of slits for increasing the membranes capacity to expand. The slits produce a mesh-like pattern in the membrane material. The amniotic derived cells deliver to the wound electrolytes, growth factors, carbohydrates, lipids, proteins, amino acids, lactate, pyruvate, enzymes, hormones and other factors useful in wound repair. The membrane material provides a scaffolding structure supporting cell growth, prevents microbial infection and decreases the rate of passive evaporative water and heat loss. The combination of the amniotic derived cells and the membrane material protects the wound and promotes cell regeneration.

Abstract: The present invention relates to the isolation, propagation and use of prenatal stem cells. The cells are CD105 negative. In certain embodiments the cells are also SSEA-4 positive or negative, and c-kit negative. The cells may be isolated from a prenatal sample, for instance third trimester amniotic fluid or placental membrane. The cells may be combined with a biologically compatible solution or a biologically compatible matrix and utilized to treat a human subject. The invention also contemplated enriched populations of prenatal stem cells. The enriched cell population may be propagated in the appropriate culture medium and the resulting progeny cells utilized therapeutic applications.

Abstract: Disclosed herewith is a method for inducing angiogenesis using modified placental tissue or an extract thereof to treat conditions other than cardiovascular conditions.

Abstract: The invention relates to a strain of Bacteroides uniformes with registration number CECT 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of Bacteroides uniformes, preferably CECT 7771, or of the cellular constituents, metabolites and/or secreted molecules of said strain, or of a composition comprising same, for the prevention and/or treatment of alterations such as excess weight, obesity, adipocyte hypertrophy, hepatic steatosis or fatty liver, dyslipidemia, hyperglycemia, insulin resistance and diabetes, metabolic syndrome, hypertension, cardiovascular diseases, dysfunction of the immune system, reduced defenses against infections, and imbalance in the composition of the intestinal microbiota.

Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: Bacillus and Lactobacillus strains and methods that are useful for improving the performance of aquatic animals. The invention also discloses Bacillus and Lactobacillus strains and methods that are useful for inhibiting or slowing the growth of a pathogenic agent in an aquatic animal.

Abstract: Described are strains including Enterococcus faecium strain 8G-1 (NRRL B-50173), Enterococcus faecium strain 8G-73 (NRRL B-50172), Bacillus pumilus strain 8G-134 (NRRL B-50174) and strains having all of the identifying characteristics of each of these strains. One or more of the strains can be used to reduce negative energy balance in a ruminant. They can also be used to improve other measures of ruminant health and/or performance. Methods of using the strains, alone and in combination, are described. Methods of making the strains are also provided.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

Abstract: Dietary, health, and/or nutritional supplements provide various formulations of mushrooms grown in fermented soy, with or without rice flour, optionally in combination with sweetener(s), curcumin, and various other herbs and spices. Certain embodiments or compositions may be in liquid, beverage, solid, paste or powder forms. In certain embodiments the supplements contain mushroom species grown in fermented soy in the presence of certain bacterial species and optionally rice or rice flour. In some embodiments, other ingredients that may be present include one or more of curcumin, desmethoxycurcumin and bis desmethoxycurcumin or all three curcumins. Certain embodiments may be used to treat or provide symptomatic relief from a variety of maladies ranging from malnutrition to mood related disorders to metabolic support and other more severe conditions as described herein.

Abstract: The present invention relates to a method for producing roasted red ginseng, having increased contents of a specific ginsenoside and sugar as compared with unroasted ginseng, which comprises the steps of: primarily roasting a fresh ginseng at 120-230° C. for 20-40 minutes by introducing the fresh ginseng into an oven; and secondarily roasting the primarily roasted red ginseng at 150-250° C. for 20-40 minutes under the pressure of 0.01-0.1 kgf/cm2, and to a roasted red ginseng produced by the said method.

Abstract: The present invention relates to a new incense extract wherein only traces of boswellic acids and resins are present, a process for the preparation of such extract, compositions comprising it, and the use of the extract and of the compositions for the protection of the skin or the mucous membranes.

Abstract: The present invention relates to a base powder for preparing functional beverages, soft drinks or an additive for food products, which is made with red raspberry from Rubus idaeus and with clinoptilolite zeolite contained in the ZAM® (activated micronized zeolite). The powder is prepared with dehydrated fruit juice. The raspberry juice extract is obtained by slowly heating (without exceeding 70° C.) a pot containing the ground fruit or a receptacle with fruit, using the bain-marie method, without exceeding 70° C. The juice is stabilized, dehydrated, optionally mixed with sugar substitutes, sweeteners or fiber, and, lastly, homogenized. The object of the present invention is to provide a food-grade base powder of natural origin that is totally different from current presentations of red raspberry on the market.

Abstract: The present invention relates to an antimicrobial composition derived from a natural substance. Since the composition effectively suppresses Filobasidium, an organism that has been newly identified as causing dandruff, the present invention can effectively prevent and/or treat seborrhoeic dermatitis and dandruff. Also, since the antimicrobial composition of the present invention includes a natural substance as an active ingredient, little consumer aversion will result. Also, it is expected that the antimicrobial composition of the present invention can be used for developing an antidandruff agent having a reduced content of materials which are typically used as antidandruff agents and the safety of which is questionable.

Abstract: A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator, glutathione modulator, neurotransmitter modulator and a DNA modulator, the vibrational platform comprising a plurality of herbs that are subjected to harmonic oscillation in the range of approximately 102 GHz-250 GHz for a period of time in the range of approximately 3-5 hrs.

Abstract: Phytochemicals of the grape, including trans-resveratrol, trans-viniferin, and oligostilibines are obtained from vineyard waste. Also, a dry powder or granular form of food supplement is provided including the phytochemicals obtained from vineyard waste, along with red wine and raw grape juice demonstrates high values of anti-oxidants. A method of making this food supplement includes solvent extraction from vineyard waste, combination with products of the grape fruit, and by vacuum drying without detrimental overheating.

Abstract: An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved NO production enhancing effect is provided. A NO production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.

Abstract: Provided herein are methods of reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell or subject. The methods include contacting the cell with or administering to the subject one or more proteasome inhibitors, and contacting the cell with or administering to the subject one or more reactivating agents. Also provided are methods of treating an HIV infection in a subject. The methods include administering to the subject one or more proteasome inhibitors, administering to the subject one or more reactivating agents and administering to the subject one or more anti-retroviral agents.

Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.

Abstract: The present invention disclose a lyophilized pharmaceutical formulation comprising antibacterial agent, daptomycin as active and tocopheryl phosphate hydrolysate mixture with improved reconstitution time for parental administration and to the process of preparation thereof. Daptomycin is a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name is N-decanoyi-L-tryptophyl-Dasparaginyl-L-aspartyi-L-threonylgly? D,-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanines 1-lactone.

Abstract: The present invention relates to methods of treating Asthma using Semaphorin 3A. The invention further relates to assessing Asthma severity or treatment efficacy, comprising determining Semaphorin 3A level in a biological sample of a subject afflicted with Asthma.

Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.

Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.

Abstract: The present invention is directed to a transgenic probiotic microorganism genetically engineered to express and secrete cystatin, wherein said cystatin is preferably comprises or consists of: an amino acid sequence with SEQ ID NO. 1 to 3; and an amino acid sequence that is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical and most preferably at least 99% identical to an amino acid sequence with SEQ ID NO. 1 to 3, and to its use for treatment of gastrointestinal inflammatory diseases.

Abstract: The present invention relates, in general, to stem cells and, in particular, to a hematopoietic stem cell (HSC) growth factor and to methods of using same.

Abstract: The present invention provides methods for treating hair loss, treating, inhibiting, or suppressing a degenerative skin disorder, treating androgenetic alopecia (AGA), generating new hair follicles (HF), and increasing the size of existing HF. The methods comprise epidermal disruption or administration of wnt, and administration of a fibroblast growth factor-9 polypeptide or another compound that upregulates sonic hedgehog gene signaling.

Abstract: Compositions and methods for producing autologous brown adipose cells in vitro or in vivo are provided. In particular, a drug delivery device is described that recruits adipose stem cells (ASCs) to a site in the body of a subject. These ASCs may then be isolated and induced to differentiate into autologous brown adipose cells. Alternatively, the drug delivery device may also include differentiation factors that induce differentiation of the recruited ASCs into brown adipose cells in vivo. The brown adipose cells produced by these methods may be used therapeutically to treat conditions, such as obesity and diabetes.

Abstract: Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.

Abstract: The invention provides methods of treating neoplasia, for example bladder cancer, by administering an IL-2 fusion protein and one or more therapeutic agents, where the IL-2 fusion protein does not necessarily have to target the neoplasia.

Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.

Abstract: The present technology generally is directed to methods for treating mild brain injury and other neurological disorders in a subject. The methods can include administering to the subject an effective amount of a compound comprising ghrelin. The present technology is also generally directed to methods for treating mild brain injury and other neurological disorders in a subject, for example, by administering to the subject an effective amount of a compound comprising ghrelin modified to include octanoic acid or by limiting the carbon 14 content.

Abstract: The present invention relates to glucagon peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of hypoglycaemia, such as a diabetic hypoglycaemic adverse event. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one glutathione; and at least one glucagon peptide that is non-covalently bound to the corona.

Abstract: Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.

Abstract: The present invention relates to insulin- and insulin analogue-carrying nanoparticles formulated together with or for use with free insulin or with an insulin analogue, such as a rapidly-acting insulin analogue. The compositions of the present invention find use in medicine, particularly in glycemic control, e.g. for controlling blood glucose levels in diabetic subjects. Nanoparticle compositions of the invention, formulated together with or for use with free insulin or with an insulin analogue, comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one carbohydrate moiety; and at least one insulin peptide and/or insulin analogue peptide that is non-covalently bound to the corona.

Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.

Abstract: Disclosed are compositions and methods related to Factor VIII.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A composition for reduced scar formation of wounds includes hydrolyzed collagen and one or more supplemental ingredients, including, lipoic acid, a zinc component, and a glucosamine component. The composition may facilitate inhibition of scar formation during wound healing. The composition may be used, for example, as a topical dressing for a wound, including, an acute or chronic wound.

Abstract: The method and composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, preferably, high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof.

Abstract: The invention relates to a modified human CYP4B1 protein and a nucleic acid encoding for the modified human CYP4B1 protein. The invention further relates to an expression vector comprising a nucleic acid encoding for a modified human CYP4B1 protein, as well as to a cell comprising a modified CYP4B1 protein. In addition, the invention relates to a modified human CYP4B1 protein for use in treating transplantation induced graft-versus-host-disease (GvHD), and to 4-ipomeanol (4-IPO) for use in killing a cell.